2026-05-13——
Owkin signs three-year K Pro licensing agreement with AstraZeneca and will build AI agents
A short entry: a summary of the public record, checked against its sources, not yet read and analysed by Gianluca. How the register works
On 13 May 2026, Owkin announced a three-year agreement licensing its K Pro AI Scientist to AstraZeneca, under which Owkin will lead end-to-end development of biopharma AI agents running on K Pro and integrated within AstraZeneca's IT infrastructure and decision workflows.
What happened
- Announced 13 May 2026 as a three-year licensing agreement for K Pro between Owkin and AstraZeneca.
- Owkin will lead end-to-end development of AI agents to run on K Pro, integrated within AstraZeneca's IT infrastructure and decision workflows.
- The agents are intended to help AstraZeneca's decision-making teams with complex competitive intelligence questions, within established governance, security, and enterprise standards.
- The agreement builds on prior Owkin-AstraZeneca work developing an AI gBRCA pre-screen solution for breast cancer.
- Results published at ESMO found the BRCAura RUO solution ruled out approximately 40% of patients unlikely to carry gBRCA mutations with 93% sensitivity.
- The BRCAura work continues at Waiv, the recent spin-out of Owkin's diagnostic division.
Sources
- owkin.com — primary
Announced 2026-05-13